

FIG. 1




FIG. 2




FIG. 3




FIG. 4




FIG. 5




FIG. 6




FIG. 7






FIG. 8a



pA2HG1apgpt

FIG. 8b



pA2HuKapgpt

FIG. 9a




FIG. 9b




FIG. 10a




FIG. 10b




FIG. 11




FIG. 12




FIG. 13

1 Val Arg Ser Ser Arg Thr Pro Ser Asp Lys Pro Val Ala His Val Val Ala Asn Pro
 10
 21 Gln Ala Glu Gly Gln Leu Gln Trp Leu Asn Arg Arg Ala Asn Ala Leu Leu Ala Asn Gly
 30
 41 Val Glu Leu Arg Asp Asn Gln Leu Val Val Pro Ser Glu Gly Leu Tyr Leu Ile Tyr Ser
 50
 61 Gln Val Leu Phe Lys Gly Gln Gly Cys Pro Ser Thr His Val Leu Leu Thr His Thr Ile
 70
 81 Ser Arg Ile Ala Val Ser Tyr Gln Thr Lys Val Asn Leu Leu Ser Ala Ile Lys Ser Pro
 90
 101 Cys Gln Arg Glu Thr Pro Glu Gly Ala Glu Ala Lys Pro Trp Tyr Glu Pro Ile Tyr Leu
 110
 121 Gly Gly Val Phe Gln Leu Glu Lys Gly Asp Arg Leu Ser Ala Glu Ile Asn Arg Pro Asp
 130
 141 Tyr Leu Asp Phe Ala Glu Ser Gly Gln Val Tyr Phe Gly Ile Ile Ala Leu
 150

FIG. 14a




FIG. 14b




FIG. 15

1	Val Arg Ser Ser Arg Thr Pro Ser Asp Lys Pro Val Ala His Val Val Ala Asn Pro	10
21	Gln Ala Glu Gly Gln Leu Gln Trp Leu Asn Arg Arg Ala Asn Ala Leu Leu Ala Asn Gly	30
41	Val Glu Leu Arg Asp Asn Gln Leu Val Val Pro Ser Glu Gly Leu Tyr Leu Ile Tyr Ser	50
61	Gln Val Leu Phe Lys Gly Gln Gly Cys Pro Ser Thr His Val Leu Leu Thr His Thr Ile	70
81	Ser Arg Ile Ala Val Ser Tyr Gln Thr Lys Val Asn Leu Leu Ser Ala Ile Lys Ser Pro	90
101	Cys Gln Arg Glu Thr Pro Glu Gly Ala Glu Ala Lys Pro Trp Tyr Glu Pro Ile Tyr Leu	110
121	Gly Gly Val Phe Gln Leu Glu Lys Gly Asp Arg Leu Ser Ala Glu Ile Asn Arg Pro Asp	130
141	Tyr Leu Asp Phe Ala Glu Ser Gly Gln Val Tyr Phe Gly Ile Ile Ala Leu	150

Figure 16




Figure 17A

CA2 LIGHT CHAIN VARIABLE REGION SEQUENCE

GACATCTTGCTGACTCAGTCTCCAGCCATCCTGTCTGTGACTCCAGGAGAAAGAGTCAGT
AspIleLeuLeuThrGlnSerProAlaIleLeuSerValSerProGluArgValSer

TTCTCCTGCACGGCCAGTCAGTTCCTTGGCTCAAGCATCCACTCGGTATCAGCAAACAACA
PheSerCysArgAlaSerGlnPheValGlySerSerIleHisTrpTyrGlnGlnArgThr

AAATCCTTCTCCAAGGCTTCTCATAAAGTATGCTTCTGAGTCTATGTCTGGGATCCCTTCC
AsnGlySerProArgLeuLeuIleLysTyrAlaSerGluSerMetSerGlyIleProSer

AGGTTTACTGGCAGTGGATCAGGCACAGATTTTACTCTTACCATCAACACTGTGGAGTGT
ArgPheSerGlySerGlySerGlyThrAspPheThrLeuSerIleAsnThrValGluSer

GAAGATATTGCAGATTATTAGTGTCAAGAAAGTCATAGCTGCCCATTCACCTTCCGCTCC
GluAspIleAlaAspTyrTyrCysGlnGlnSerHisSerTrpProPheThrPheGlySer

CGGACAAATTTGCAAGTAAAA
GlyThrAsnLeuGluValLys

CAACTCAAGCTTCACCACTCTCCACCACGCTTCCTCCAACCTCCACCATCCATCAAATC
GluValLysLeuGluGluSerGlyGlyGlyLeuValGlnProGlyGlySerMetLysLeu

TCCTGTGTTCCTCTGGATTCAATTTCACTAACCACTGGATGAAGTGGGTCCGCCAGTCT
SerCysValAlaSerGlyPheIlePheSerAsnHisTrpMetAsnTrpValArgGlnSer

CCAGACAAGGGGCTTGAGTGGGTTCCTCAAATTACATCAAAATCTATTAATTCTGCAACA
ProGluLysGlyLeuGluTrpValAlaGluIleArgSerLysSerIleAsnSerAlaThr

CATTATGCCGAGTCTGTGAAAGGGAGGTTCAACCATCTCAAGAGATGATTCCAAAAGTCT
HisTyrAlaGluSerValLysGlyArgPheThrIleSerArgAspAspSerLysSerAla

GTCTACCTCGAAATGACCGACTTAAGAACTGAAGACACTGGCGTTTATTACTGTTCCAGG
ValTyrLeuGlnMetThrAspLeuArgThrGluAspThrGlyValTyrTyrCysSerArg

AATTACTACGCTAGTACCTACGACTACTCGCGCCAAGCCACCAGTCTCAGAGTCTCC
AsnTyrTyrGlySerThrTyrAspTyrTrpGlyGlnGlyThrThrLeuThrValSer

Figure 17B

anti-TNF Trial

EMS




FIG-18

anti-TNF Trial

Pain





FIG. 19

anti-TNF Trial

Ritchie Articular Index



anti-TNF Trial

Swollen Joints




FIG 21

anti-TNF Trial

CRP




FIG. 22

anti-TNF Trial

ESR




FIG 23

anti-TNF Trial

Index of Disease Activity




FIG 24

SWOLLEN JOINT COUNTS IN PATIENTS WITH RA FOLLOWING CA2 ADMINISTRATION



FIGURE 2-5

EFFECT OF CA2 ADMINISTRATION ON CRP LEVELS IN PATIENTS WITH RA





FIGURE 26

27 A



27 B




FIGURE 27 A-B




FIGURE 28

08 192861




FIGURE 29

08 192861




FIGURE 30

08 192861




FIGURE 31

08 192861





FIGURE 32

A)



FIGURE

33

A

B)




FIGURE 33 B

C)




FIGURE 33 c






FIGURE 34

08 192861









FIGURE

35 A

08 192861

B)



FIGURE

35 B